BCL2L1 and ovarian carcinoma: This study aimed to evaluate whether belinostat, an FDA‐approved pan‐HDAC inhibitor, could increase Bim, Puma, and/or Noxa expression and induce ovarian cancer cell death, either alone or in combination with strategies targeting Bcl‐xL or Mcl‐1.